NexGel (NASDAQ:NXGL) vs. Microbot Medical (NASDAQ:MBOT) Head-To-Head Comparison

Microbot Medical (NASDAQ:MBOT) and NexGel (NASDAQ:NXGL) are both small-cap medical companies, but which is the better stock? We will contrast the two businesses based on the strength of their profitability, valuation, earnings, dividends, risk, analyst recommendations and institutional ownership.

Earnings and Valuation

This table compares Microbot Medical and NexGel”s top-line revenue, earnings per share and valuation.

	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Microbot Medical	N/A	N/A	-$13.14 million	($0.26)	-6.88
NexGel	$11.42 million	0.36	-$3.00 million	($0.40)	-1.11

NexGel has higher revenue and earnings than Microbot Medical. Microbot Medical is trading at a lower price-to-earnings ratio than NexGel, indicating that it is currently the more affordable of the two stocks.

Volatility & Risk

Microbot Medical has a beta of 1.04, indicating that its share price is 4% more volatile than the S&P 500. Comparatively, NexGel has a beta of 0.76, indicating that its share price is 24% less volatile than the S&P 500.

Analyst Recommendations

This is a breakdown of recent recommendations and price targets for Microbot Medical and NexGel, as provided by MarketBeat.

	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Microbot Medical	1	1	2	1	2.60
NexGel	1	0	1	0	2.00

Microbot Medical presently has a consensus target price of $6.62, suggesting a potential upside of 270.11%. NexGel has a consensus target price of $2.00, suggesting a potential upside of 348.93%. Given NexGel’s higher possible upside, analysts clearly believe NexGel is more favorable than Microbot Medical.

Insider & Institutional Ownership

16.3% of Microbot Medical shares are held by institutional investors. Comparatively, 2.2% of NexGel shares are held by institutional investors. 4.7% of Microbot Medical shares are held by insiders. Comparatively, 23.4% of NexGel shares are held by insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a company will outperform the market over the long term.

Profitability

This table compares Microbot Medical and NexGel’s net margins, return on equity and return on assets.

	Net Margins	Return on Equity	Return on Assets
Microbot Medical	N/A	-21.84%	-20.71%
NexGel	-28.54%	-64.29%	-29.64%

Summary

Microbot Medical beats NexGel on 9 of the 14 factors compared between the two stocks.

About Microbot Medical

Microbot Medical Inc., a pre-clinical medical device company, engages in the research, design, and development of robotic endoluminal surgery devices targeting the minimally invasive surgery space. The company offers LIBERTY, an endovascular robotic surgical system which allows physicians to conduct a catheter-based procedure from outside the catheterization laboratory, and avoid radiation exposure, physical strain, and the risk of cross contamination for use in cardiovascular, peripheral, and neurovascular spaces. It also provides NovaCross, an intellectual property and technology in the field of intraluminal revascularization devices with anchoring mechanism and integrated microcatheter. The company has a strategic collaboration agreement with Stryker Corporation for technology co-development. Microbot Medical Inc. was founded in 2010 and is based in Braintree, Massachusetts.

About NexGel

NEXGEL, Inc. manufactures high water content, electron beam cross-linked, and aqueous polymer hydrogels and gels. Its products are used for wound care, medical diagnostics, transdermal drug delivery, and cosmetics. The company was formerly known as AquaMed Technologies, Inc. and changed its name to NEXGEL, Inc. in November 2019. The company was incorporated in 2009 and is based in Langhorne, Pennsylvania.